GLP-1 diabetes drugs might curb Alzheimer's brain plaques, review finds

A systematic review of preclinical studies and two small human trials suggests GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide, semaglutide) consistently reduce Alzheimer’s-related proteins amyloid-beta and tau in lab and animal models, indicating potential for preventive effects. However, human data are limited and do not show cognitive reversal, so larger early-intervention trials are needed to determine if these diabetes/weight-loss drugs can prevent or slow Alzheimer's progression.